Multiple sclerosis (MS) is universally found to be more prevalent in women than men. This
has led to extensive studies of differences in the immune system or nervous system between …

Inflammatory bowel disease (IBD) has a peak age of diagnosis before the age of 35 years.
Concerns about infertility, adverse pregnancy outcomes, and heritability of IBD have …

Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …

Importance Women with multiple sclerosis (MS) experience an elevated risk of relapse after
giving birth. The effect of exclusive breastfeeding on postpartum risk of MS relapse is …

Importance Natalizumab reduces multiple sclerosis relapses very effectively; however,
severe disease activity may return once natalizumab treatment is withdrawn, as …

Background Patients with multiple sclerosis (MS) or Crohn's disease (CD) being treated with
natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are …

Objective: To systematically review the literature regarding safety of disease-modifying drug
(DMD) use during pregnancy on perinatal and developmental outcomes in offspring of …

Objective To assess possible adverse effects on breastfed infants of mothers receiving
monoclonal antibodies (MAbs) during pregnancy and/or lactation. Methods We identified 23 …

Objective: To report outcomes of pregnancies that occurred during the fingolimod clinical
development program. Methods: Pregnancy outcomes from phase II, phase III, and phase IV …

A number of studies have reported flare-up of multiple sclerosis (MS) disease activity after
cessation of natalizumab, increasing to a level beyond the pre-natalizumab treatment level …